Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 17%
Hold 58%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a biopharmaceutical firm with a strong focus on developing and commercializing cancer treatments, including their approved drug Cabometyx and upcoming catalysts such as the STELLAR-316 and STELLAR-304 trials. With a diverse pipeline and focus on small molecule-based approaches, the company has positioned itself for potential long-term success, although there are inherent risks in the development of oncology drugs.

Bears say

Exelixis is facing a major FDA decision on December 3 and the approval of Cometriq for 3L+ mCRC could potentially open up a ~$1B market opportunity, making it a key driver for the company's future growth and valuation. Despite mixed results in a recent study, the company's strong cabo scripts and increasing sales expectations could also provide a boost to its stock price. However, concerns remain around the effectiveness of its drug in patients with liver metastases and the potential for consolidation in the highly competitive market, leading to a negative outlook on the stock. In addition, the current price target for the stock is at $55, reflecting a potentially overvalued stock.

Exelixis (EXEL) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 17% recommend Buy, 58% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 12 analysts, Exelixis (EXEL) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.